Nuevolution’s application for delisting from Nasdaq Stockholm approved

As previously communicated by Nuevolution AB (publ) (“Nuevolution”) by a press release published on 11 July 2019, the board of directors of Nuevolution has resolved to apply for delisting of Nuevolution’s shares from Nasdaq Stockholm. Today, Nasdaq Stockholm approved the application and resolved that the last day of trading in Nuevolution’s shares will be 26 July 2019.

For more information, please contact:

Alex Haahr Gouliaev, CEO
Phone: +45 7020 0987
Email: ahg@nuevolution.com

Johnny Stilou, CFO
Phone: +45 8877 5973
Email: jost@nuevolution.com

Information about Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and develops its programs alone and in collaboration with pharmaceutical and biotechnology companies to seek future benefit for patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important diseases targets within severe inflammatory diseases and cancer.

This information was released for publication at 15.00 CEST on 12 July 2019.

Nuevolution AB (publ) is listed at Nasdaq in Stockholm, Sweden (ticker: NUE). More information about Nuevolution can be found on: www.nuevolution.com.